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ORIGINAL ARTICLE
Pomalidomide, bortezomib and low-dose dexamethasone in
lenalidomide-refractory and proteasome inhibitor-exposed
myeloma
PG Richardson1, CC Hofmeister2, NS Raje3, DS Siegel4, S Lonial5, J Laubach1, YA Efebera2, DH Vesole4, AK Nooka5, J Rosenblatt6,
D Doss1, MH Zaki7, A Bensmaine7, J Herring7, Y Li7, L Watkins7, MS Chen7 and KC Anderson1
This phase 1 dose-escalation study evaluated pomalidomide, bortezomib (subcutaneous (SC) or intravenous (IV)) and low-dose
dexamethasone (LoDEX) in lenalidomide-refractory and proteasome inhibitor-exposed relapsed or relapsed and refractory multiple
myeloma (RRMM). In 21-day cycles, patients received pomalidomide (1–4 mg days 1–14), bortezomib (1–1.3 mg/m2 days 1, 4, 8 and
11 for cycles 1–8; days 1 and 8 for cycle ⩾ 9) and LoDEX. Primary endpoint was to determine the maximum tolerated dose (MTD).
Thirty-four patients enrolled: 12 during escalation, 10 in the MTD IV bortezomib cohort and 12 in the MTD SC bortezomib cohort.
Patients received a median of 2 prior lines of therapy; 97% bortezomib exposed. With no dose-limiting toxicities, MTD was deﬁned
as the maximum planned dose: pomalidomide 4 mg, bortezomib 1.3 mg/m2 and LoDEX. All patients discontinued treatment by
data cutoff (2 April 2015). The most common grade 3/4 treatment-emergent adverse events were neutropenia (44%) and
thrombocytopenia (26%), which occurred more frequently with IV than SC bortezomib. No grade 3/4 peripheral neuropathy or
deep vein thrombosis was reported. Overall response rate was 65%. Median duration of response was 7.4 months. Pomalidomide,
bortezomib and LoDEX was well tolerated and effective in lenalidomide-refractory and bortezomib-exposed patients with RRMM.
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INTRODUCTION
The introduction of immunomodulatory agents and proteasome
inhibitors (PIs) has transformed multiple myeloma (MM) therapy
over the past decades, with signiﬁcant improvement in response
rates, progression-free survival (PFS) and overall survival (OS).1,2
However, relapse is inevitable in almost all patients, and
recurrence of MM is typically more aggressive with each
subsequent relapse, justifying the development of new combina-
tions mainly in MM-refractory disease.3
In preclinical studies, the immunomodulatory agents thalido-
mide and lenalidomide were each shown to potentiate the activity
of bortezomib in combination with dexamethasone.4,5 Results
from clinical studies conﬁrmed the antimyeloma activity of the
combination of lenalidomide and bortezomib in patients with
MM.6–8 The phase 3 SWOG S0777 trial demonstrated a signiﬁ-
cantly longer PFS (median of 43 vs 30 months; two-sided
P= 0.0037) and OS (median of 75 vs 64 months; two-sided
P= 0.025) with the triplet combination of lenalidomide, bortezo-
mib and dexamethasone compared with lenalidomide and
dexamethasone in patients with newly diagnosed MM.8 Similarly
in patients with relapsed or relapsed and refractory MM (RRMM),
the combination of lenalidomide, bortezomib and low-dose
dexamethasone (LoDEX) has displayed antimyeloma activity, with
an overall response rate (ORR) of 64% and a 6-month PFS rate of
75%.7 More than half of the patients in the trial had prior exposure
to bortezomib, and three-quarters had prior exposure to
thalidomide, indicating that the combination of lenalidomide
and bortezomib could achieve responses in patients previously
exposed to thalidomide and/or bortezomib.7
Pomalidomide is an oral IMiD immunomodulatory agent with
signiﬁcant activity in RRMM.9 With direct tumoricidal, potent
immune-activating, antiangiogenic and anti-inﬂammatory activ-
ities, pomalidomide is being extensively investigated in combina-
tion with other agents that have complementary mechanisms of
action.
The approved treatment schedule of pomalidomide is 4 mg/day
on days 1–21 of a 28-day cycle, given in combination with LoDEX.
The regimen is approved in the United States for patients with MM
who have received ⩾ 2 prior therapies including lenalidomide and
a PI and have had disease progression within 60 days of
completing their last therapy.10–13 In patients with RRMM who
were heavily pretreated with lenalidomide and bortezomib,
treatment with pomalidomide and LoDEX delayed disease
progression (median PFS, 4.0 vs 1.9 months; hazard ratio, 0.48;
Po0.0001) and extended survival (median OS, 12.7 vs 8.1 months;
hazard ratio, 0.74; P= 0.0285) compared with high-dose
dexamethasone.11–13 The efﬁcacy and tolerability of pomalido-
mide were maintained in all subgroups, including the elderly,14
patients with high-risk cytogenetics15,16 and those with moderate
renal impairment.17,18
The current study was a prospective phase 1, multicenter, dose-
escalation trial of pomalidomide, bortezomib and LoDEX in
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lenalidomide-refractory and PI-exposed patients. During the trial
in 2012, subcutaneous (SC) bortezomib was approved by the US
Food and Drug Administration based on its noninferiority to
intravenous (IV) bortezomib and improved safety proﬁle in
RRMM.19 Therefore, an additional cohort of patients receiving
pomalidomide, SC bortezomib and LoDEX was included; however,
this study was not designed to compare SC vs IV bortezomib. We
report the results of patients treated with pomalidomide, IV
bortezomib and LoDEX in the escalation cohorts, the maximum
tolerated dose (MTD) plus IV bortezomib cohort, the MTD plus SC
bortezomib cohort and the entire study population.
MATERIALS AND METHODS
Study participants
This phase 1, open-label, dose-escalation study (MM-005; ClinicalTrials.gov
NCT01497093) was conducted in 6 centers in the United States. Patients
enrolled into the study were aged ⩾ 18 years with an Eastern Cooperative
Oncology Group performance status of ⩽ 2 and were required to have a
documented diagnosis of MM with measurable disease by serum (⩾ 0.5 g/
dl) and/or urine protein (⩾ 200 mg/24 h) electrophoresis. All patients must
have received 1–4 prior antimyeloma therapies. Prior treatment must have
included ⩾ 2 consecutive cycles of lenalidomide and ⩾ 2 consecutive cycles
of a PI. Patients were required to be refractory to the last lenalidomide-
containing regimen but were not allowed to be refractory to bortezomib
o1.3 mg/m2 twice weekly either as a single agent or in combination.
Refractory status/disease was deﬁned as documented disease progression
during treatment or within 60 days after the last dose of either agent given
as monotherapy or with combination treatment.
Patients were ineligible if they had previously received pomalidomide;
had hypersensitivity to thalidomide, lenalidomide, bortezomib or
dexamethasone; or had grade ⩾ 3 rash during prior therapy with
thalidomide or lenalidomide. Patients with grade ⩾ 2 peripheral
neuropathy or a history of congestive heart failure, myocardial infarction
within 12 months of starting the study or unstable or poorly controlled
angina pectoris were excluded. Patients with any of the following
laboratory abnormalities were also ineligible for study participation:
absolute neutrophil count of o1000/μl; platelet count of o75 000/μl for
patients in whom o50% of bone marrow nucleated cells were plasma
cells or o30 000/μl for patients in whom ⩾ 50% of bone marrow
cellularity were plasma cells; creatinine clearance of o45 ml/min
according to the Cockcroft-Gault formula or on collection of 24-h urine;
hemoglobin of o8 g/dl; corrected serum calcium of 43.4 mmol/l; total
bilirubin level of 41.5 × upper limit of normal; or liver enzyme levels of
43 × upper limit of normal. Additional exclusion criteria included other
malignancies unless the patient was disease free for ⩾ 5 years
or the malignancy included basal cell or squamous cell skin cancer,
in situ cervical, breast or prostate cancer (T1a or T1b or otherwise
considered curable); gastrointestinal disease that may interfere with
pomalidomide absorption; plasmapheresis, major surgery, radiation
therapy or any antimyeloma treatment for ⩽ 14 days of therapy; other
conditions that require chronic steroids or immunosuppression; or
known infection with human immunodeﬁciency virus or hepatitis B or
C virus.
This study was approved by the institutional review board or
independent ethics committee at each participating center before
initiation of any study procedures and was conducted in accordance with
the principles for Good Clinical Practice (as outlined by the International
Conference on Harmonisation E6 requirements) and the Declaration of
Helsinki. Before the start of the study, all patients provided written
informed consent. All authors had access to the primary clinical trial data
and, with the sponsor, analyzed and interpreted the data.
Study design and treatment
This dose-escalation trial used a 3+3 design to determine the primary
endpoint of MTD for the combination of pomalidomide, IV bortezomib and
LoDEX in patients with RRMM. There were 5 dosing cohorts (Figure 1).
Patients in cohort 5 received the maximum planned dose (MPD) of
pomalidomide 4 mg, IV bortezomib 1.3 mg/m2 and LoDEX 20 mg (10 mg
for patients aged 475 years). Secondary endpoints included safety, ORR
(better than or equal to partial response (PR)), time to response (TTR) and
duration of response (DOR).
Oral pomalidomide was administered on days 1–14 of a 21-day cycle. IV
bortezomib was administered on days 1, 4, 8 and 11 for cycles 1–8 and
then on days 1 and 8 for cycles ⩾ 9. Oral LoDEX was administered on days
of and after bortezomib dosing. During the study, SC bortezomib became
available with a favorable safety proﬁle and low incidence of peripheral
neuropathy. The study protocol was amended to include a cohort of
patients who received SC bortezomib as part of the pomalidomide,
bortezomib and LoDEX regimen at the MTD that was established with the
IV formulation. After completing the ﬁrst cycle of treatment, patients could
continue the study at the assigned dose level until disease progression or
unacceptable toxicity. Patients were evaluated every 21 days until and
28 days after treatment discontinuation.
In addition to study therapy, patients were required to receive
thromboembolism prophylaxis (aspirin or low-molecular-weight heparin)
and antiviral prophylaxis (for example, acyclovir) was recommended.
Patients were allowed to receive red blood cell and platelet transfusions as
needed and bisphosphonate therapy for myeloma-associated bone
disease. The prophylactic use of hematopoietic growth factors was not
allowed during cycle 1. Chronic use of steroids or other
Figure 1. MM-005 trial design. MM-005 included 5 dose-escalation cohorts. Three patients were treated at each dose level, and 7 additional
patients were treated at the MTD in the expansion phase of the trial. An additional cohort of patients treated with SC bortezomib (BORT) was
included (n= 12). Patients were evaluated every 21 days until treatment discontinuation. Patients will undergo long-term follow-up for OS
and secondary primary malignancies (SPM). *For cycles 1–8, then D1 and D8 for cycle ⩾ 9. †For cycles 1–8, then D1–2 and
D8–9 for cycles ⩾ 9. ‡10 mg for patients aged 475 years. POM, pomalidomide.
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immunosuppressive therapies was not permitted. Pomalidomide dose
interruptions and reductions per protocol were similar to those in the
NIMBUS phase 3 trial and have been described previously.10,13,20 Dose
modiﬁcations for bortezomib and dexamethasone were in accordance
with their respective package inserts and institutional guidelines.21
The MTD was deﬁned as the dose level preceding the dose level at
which a dose-limiting toxicity (DLT) was observed in ⩾ 2 patients in the
ﬁrst 21-day cycle. Once the MTD was identiﬁed, an additional 6 patients
were treated at the MTD to conﬁrm safety and assess preliminary
efﬁcacy of pomalidomide, IV bortezomib and LoDEX. If a patient had a
dose reduction of pomalidomide or bortezomib or discontinued
treatment during cycle 1 for any reason other than a DLT, missed
multiple doses of study drug, or received hematopoietic growth factors
during cycle 1 before a DLT was declared, the patient was replaced
within the given dose-escalation cohort for the purposes of determining
the MTD.
A DLT was deﬁned as any of the following toxicities occurring during the
ﬁrst cycle of treatment: grade 4 neutropenia (absolute neutrophil count of
o500/μl) lasting for 47 days, febrile neutropenia (absolute neutrophil
count of o1000/μl and temperature of 438.3 °C or a temperature of
⩾ 38.3 °C lasting for 41 h), grade 3 thrombocytopenia (platelet count of
⩾ 25 000 to o50 000/μl) with signiﬁcant bleeding and need for
hospitalization and/or platelet transfusion, grade 4 thrombocytopenia
(platelet count of o25 000/μl) with a ⩾ 30% decrease in platelet count
from baseline and requiring41 platelet transfusion, grade 4 infection and
grade ⩾ 3 toxicities related to pomalidomide (nausea, vomiting, constipa-
tion and/or diarrhea with optimal symptomatic treatment or fatigue lasting
for 47 days).
Toxicity and response assessments
Safety was routinely monitored per protocol frequency and included
physical examinations, clinical laboratory evaluations, venous thromboem-
bolism monitoring, electrocardiograms, second primary malignancy
monitoring and adverse event (AE) monitoring. AEs were coded according
to the Medical Dictionary for Regulatory Activities, version ⩾ 14. The
severity of AEs and clinical laboratory values were graded according to the
National Cancer Institute Common Terminology Criteria for Adverse Event
(NCI CTCAE) version ⩾ 4.0, with the exception of rash, which was graded
using NCI CTCAE version 3.0. If a patient experienced an AE on multiple
occasions, the event was counted only once and by the greatest severity.
Treatment-emergent AEs (TEAEs) were deﬁned as any AEs occurring or
worsening on or after the ﬁrst dose of a study medication and within
28 days after the last dose.
Tumor response was assessed according to the International Myeloma
Working Group criteria at every cycle on day 1 starting at cycle 2 and
treatment discontinuation.22 Response assessments included measure-
ment of myeloma paraprotein by protein electrophoresis and immunoﬁxa-
tion; measurement of serum immunoglobulin, serum-free light chain and
corrected serum calcium levels; bone marrow aspiration/biopsy; radiolo-
gical imaging for lytic bone lesions; and clinical and/or radiological
measurements for extramedullary plasmacytoma.
Statistical analysis
Patient demographics, baseline disease characteristics, medical history and
prior or concomitant medications were summarized using descriptive
statistics or frequency tabulations.
Table 1. Baseline patient demographic, disease and treatment characteristics
Escalation (n= 12) MTD with IV bortezomib (n= 10) MTD with SC bortezomib (n=12) Total (N= 34)
Median age, y (range) 57.5 (36–75) 58.5 (49–67) 61 (43–76) 58.5 (36–76)
Male, n (%) 6 (50) 6 (60) 8 (67) 20 (59)
ECOG performance status, n (%)
0 5 (42) 6 (60) 8 (67) 19 (56)
1 7 (58) 4 (40) 4 (33) 15 (44)
ISS stage, n (%)a
I 1 (8) 5 (50) 6 (50) 12 (35)
II 1 (8) 1 (10) 5 (42) 7 (21)
III 3 (25) 1 (10) 0 4 (12)
Missing 7 (58) 3 (30) 1 (8) 11 (32)
β2-microglobulin (mg/l)
Median (range) 2.4 (1.3–4.4) 2.3 (1.6–6.7) 2.6 (1.4–6.5) 2.5 (1.3–6.7)
Hemoglobin (g/l)
Median (range) 113.5 (87.0–148.0) 108.5 (83.0–137.0) 123.0 (90.0–154.0) 115.0 (83.0–154.0)
Platelets, × 109/L
Median (range) 150 (56.0–254.0) 169.0 (59.0–304.0) 191.5 (96.0–298.0) 165.0 (56.0–304.0)
ANC, × 109/L
Median (range) 2.2 (1.1–3.5) 2.0 (1.2–5.4) 3.0 (0.9–6.7) 2.2 (0.9–6.7)
Presence of bone lesions
Yes/no, n (%) 9 (75)/3 (25) 6 (60.0)/4 (40.0) 9 (75.0)/3 (25) 24 (70.6)/10 (29.4)
Median prior lines of treatment (range) 2 (1–4) 2 (1–3) 1 (1–4) 2 (1–4)
⩾ 2 prior lines of treatment, n (%) 8 (67) 7 ((70) 4 (33) 19 (56)
Time from initial diagnosis (y)
Median (range) 4.0 (2.4–12.1) 4.2 (1.5–8.2) 2.0 (0.7–9.1) 3.4 (0.7–12.1)
Prior lenalidomide and PI, n (%) 12 (100) 10 (100) 12 (100) 34 (100)
Prior dexamethasone, n (%) 12 (100) 10 (100) 12 (100) 34 (100)
Prior thalidomide, n (%) 6 (50) 3 (30) 3 (25) 12 (35)
Prior bortezomib, n (%) 12 (100) 10 (100) 11 (92) 33 (97)
Prior ixazomib, n (%) 0 1 (10) 1 (8) 2 (6)
Prior SCT, n (%) 12 (100) 8 (80) 3 (25) 23 (68)
Abbreviations: ANC, absolute neutrophil count; ECOG, Eastern Cooperative Oncology Group; ISS, International Staging System; IV, intravenous; MTD, maximum
tolerated dose; PI, proteasome inhibitor; SC, subcutaneous; SCT, stem cell transplant. aPercentage of patients with data available.
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The efﬁcacy-evaluable population included all enrolled patients who
received ⩾ 1 dose of study medication and who had measurable disease
with serum (⩾ 0.5 g/dl) and/or urine protein (⩾ 200 mg/24 h) electrophor-
esis at baseline and at ⩾ 1 postbaseline assessment. The ORR (better than
or equal to PR), together with the relative proportions in each response
category, was summarized. For responders (better than or equal to PR),
TTR, which is deﬁned as the time from the ﬁrst date of dosing to the ﬁrst
date of documented response, and DOR, which is deﬁned as time from the
earliest date of documented response to the earliest date when disease
progression was conﬁrmed, were also summarized.
The safety population included all patients who received ⩾ 1 dose of
study medication. TEAEs, AEs leading to study medication discontinuation,
AEs leading to dose reduction/interruption, AEs related to study
medication, serious AEs and AEs leading to death were summarized by
system organ class and preferred term for each treatment group.
A summary of AEs with NCI CTCAE grade ⩾ 3, as well as the most frequent
preferred terms, are provided. All deaths and reasons for death were
summarized. Statistical analyses were conducted using SAS version ⩾ 9.1.
RESULTS
Patients and treatments
Between March 2012 and August 2014, a total of 34 patients with
RRMM were enrolled and treated. Twelve patients received treatment
in the ﬁrst 4 dose-escalation cohorts (3 patients at each dose level)
and 3 patients were initially treated at the MPD (level 5; Figure 1).
None of the ﬁrst 15 patients treated experienced a DLT, and there
was no need to replace any of the patients within the dose-escalation
cohorts. Therefore, the MTD was deﬁned as the MPD: pomalidomide
4mg, bortezomib 1.3 mg/m2 and LoDEX 20 mg (10 mg for patients
aged 475 years). The MTD cohort was subsequently expanded to
include 7 more patients for a total of 10 patients. An additional cohort
was added that comprised 12 patients treated with pomalidomide,
LoDEX and SC bortezomib at the MTD.
The results for this study are presented according to 3 patient
groupings: group 1 includes the 12 patients in the ﬁrst 4 dose-
escalation cohorts; group 2 includes 10 patients (3 patients initially
treated at the MPD level and then expanded to include 7 more
patients at the MPD level) at the MTD with IV bortezomib; and group
3 includes 12 patients at the MTD with SC bortezomib (Table 1).
Of the study patients, 59 were male and 56 and 44% had an
Eastern Cooperative Oncology Group performance status of 0 and 1,
respectively (Table 1). Median patient age was 58.5 years (range,
36–76 years). The median time from initial diagnosis was 3.4 years
(range, 0.7–12.1 years); in the MTD groups with IV bortezomib and
MTD groups with SC bortezomib, it was 4.2 years (range, 1.5–8.2
years) and 2.0 years (range, 0.7–9.1 years), respectively. All patients
were refractory to lenalidomide, and all were exposed to a prior PI
(97% bortezomib; 6% ixazomib). All patients had progressive disease
after the last myeloma regimen, and the majority (91.2%) had
Table 2. Patient disposition
Escalation (n=12) MTD with IV bortezomib (n=10) MTD with SC bortezomib (n=12) Total (N= 34)
On treatment, n (%) 0 0 0 0
Discontinued, n (%) 12 (100) 10 (100) 12 (100) 34 (100)
PD 9 (75) 6 (60) 7 (58) 22 (65)
Consent withdrawn 2 (17) 1 (10) 0 3 (9)
AE 0 1 (10)a 0 1 (3)
Death 0 0 1 (8)b 1 (3)
Lost to follow-up 0 0 1 (8) 1 (3)
Other 1 (8)c 2 (20)d 3 (25)e 6 (18)
Abbreviations: AE, adverse event; IV, intravenous; MTD, maximum tolerated dose; PD, progressive disease; SC, subcutaneous. aOne patient discontinued study
treatment in cycle 2 due to metastatic pancreatic cancer unrelated to treatment. bOne patient died due to cardiac arrest unrelated to treatment in cycle 3.
cOne patient was unable to switch to SC bortezomib. dOne patient proceeded to transplant and 1 patient discontinued for noncompliance. eTwo patients
proceeded to transplant and 1 patient discontinued due to clinical progression.
Table 3. Treatment exposure, dose interruptions and dose reductions
Escalation (n= 12) MTD with IV bortezomib (n= 10) MTD with SC bortezomib (n=12) Total (N=34)
Median duration of treatment, mo (range)
Overall 6.3 (2.8–27.6) 7.6 (1.2–18.5) 6.0 (2.1–10.6) 6.2 (1.2–27.6)
Pomalidomide 6.1 (2.7–27.6) 7.6 (1.2–18.5) 6.0 (1.4–10.6) 6.2 (1.2–27.6)
Bortezomib 5.1 (2.8–27.6) 7.6 (1.2–18.5) 5.8 (2.1–10.6) 6.1 (1.2–27.6)
Dexamethasone 5.8 (2.8–27.6) 7.6 (1.2–18.5) 5.3 (0.7–10.6) 5.9 (0.7–27.6)
Median relative dose intensity (range)
Pomalidomide 0.9 (0.6–1.0) 0.9 (0.6–1.1) 0.8 (0.2–1.0) 0.9 (0.2–1.1)
Bortezomiba 0.9 (0.5–1.1) 0.9 (0.6–1.0) 0.8 (0.4–1.0) 0.9 (0.4–1.1)
Dexamethasonea 0.7 (0.4–1.0) 0.8 (0.5–1.1) 0.5 (0.3–1.0) 0.6 (0.3–1.1)
Interruption due to TEAE, n (%)
Pomalidomide 7 (58) 9 (90) 11 (92) 27 (79)
Bortezomib 7 (58) 8 (80) 10 (83) 25 (74)
Dexamethasone 8 (67) 8 (80) 11 (92) 27 (79)
Reduction due to TEAE, n (%)
Pomalidomide 3 (25) 4 (40) 6 (50) 13 (38)
Bortezomib 5 (42) 3 (30) 7 (58) 15 (44)
Dexamethasone 9 (75) 7 (70) 8 (67) 24 (71)
Abbreviations: IV, intravenous; MTD, maximum tolerated dose; SC, subcutaneous; TEAE, treatment-emergent adverse event. aDuring the ﬁrst 8 cycles.
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progressed ⩽60 days after the last regimen. Twenty-three patients
(68%) underwent prior stem cell transplant (SCT). The median
number of prior lines of antimyeloma therapy received was 2 (range,
1–4). Compared with the IV bortezomib cohort, fewer patients in the
SC bortezomib cohort received ⩾2 prior lines of antimyeloma
treatment and prior transplant. At screening, 14 patients had
peripheral sensory neuropathy, 11 of whom had a grade 1 event.
At the time of data cutoff (2 April 2015), all patients had
discontinued study treatment (Table 2). The most common reason
for treatment discontinuation was PD in 22 patients (65%): 9 (75%)
in the dose-escalation cohort and 6 (60%) and 7 (58%) in the MTD
cohorts with IV and SC bortezomib, respectively. One patient
discontinued pomalidomide treatment due to metastatic pan-
creatic cancer diagnosed 1.1 months after study treatment
initiation, and 3 patients discontinued because they went on to
receive SCT. As of November 2016, 13 patients are in long-term
follow-up.
Treatment exposure and safety
The median duration of treatment was 6.2 months (range,
1.2–27.6 months), and the median number of treatment cycles
received was 9 (range, 2–36) for all treated patients (Table 3).
Patients in the MTD IV bortezomib cohort received a median of 11
(range, 2–19) and patients in the MTD SC bortezomib cohort
received a median of 8 (range, 3–15) cycles of treatment. The
median relative dose intensity was 0.9 for pomalidomide
throughout the study and 0.9 for bortezomib during the ﬁrst 8
cycles of treatment. The incidences of dose interruptions and
reductions due to TEAEs were 79 and 38% for pomalidomide and
74 and 44% for bortezomib, respectively. The number of dose
interruptions was similar regardless of method of bortezomib
administration. However, the number of reductions of pomalido-
mide and bortezomib dose due to TEAEs was slightly less frequent
in the IV (40 and 30%, respectively) vs SC (50 and 58%,
respectively) bortezomib cohort. Neutropenia was the most
common TEAE leading to pomalidomide dose reductions (9%).
Infections (47%), neutropenia (26%), pneumonia (9%), peripheral
sensory neuropathy (9%), dizziness (9%) and fatigue (9%) were
common TEAEs (⩾ 3 patients) leading to pomalidomide dose
interruptions. Peripheral sensory neuropathy (12%) was the most
common TEAE (⩾ 3 patients) leading to bortezomib dose
reductions, whereas interruptions were primarily due to infections
(44%), neutropenia (21%), pneumonia (12%) and fatigue (9%).
All of the 34 patients included in the safety population had ⩾ 1
TEAE; 29 (85%) had ⩾1 grade 3/4 TEAE (Table 4). Neutropenia and
thrombocytopenia were the most common grade 3/4 TEAEs. The
incidence of these events was higher in the IV bortezomib cohort
(80 and 40%, respectively) compared with the SC bortezomib
cohort (25 and 17%, respectively). Eighteen patients (53%) had
treatment-emergent peripheral neuropathy, with 6 out of 12 (50%)
in the escalation cohort, 3 out of 10 (30%) in the IV bortezomib
cohort and 9 out of 12 (75%) in the SC bortezomib cohort; none of
the events were grade 3/4. Treatment-emergent deep vein
thrombosis was uncommon (6%); no patients experienced a grade
3/4 event. One death occurred during treatment cycle 3 as a result
of cardiac arrest unrelated to study drugs.
Efﬁcacy
All 34 patients were evaluable for tumor response (Figure 2).
Disease control with at least stable disease was reported for all
patients. The ORR (better than or equal to PR) for all treated
patients was 65%. One patient in the MTD IV bortezomib cohort
had a stringent complete response (sCR) and 2 patients in the
MTD SC bortezomib cohort had a CR. Patients with sCR/CR
received 1 or 2 prior lines of therapy (Table 5). ORR was 59% for all
patients treated at the MTD: 70 and 50% in the IV and SC
bortezomib cohorts, respectively. For all responding patients
(n= 22), the median TTR was 1.0 months (range, 0.7–5.1 months)
and the median DOR was 7.4 months (95% CI, 4.4–9.6 months).
This was similar for the patients treated at the MTD: median TTR of
0.9 months (range, 0.7–3.1 months) and median DOR of
7.4 months (95% CI, 4.1-not estimable).
DISCUSSION
Preclinical and clinical studies have proven the clinical beneﬁt of
combination therapy with an immunomodulatory agent and a PI
for the treatment of patients with RRMM.4–7 In this phase 1 trial,
Table 4. Grade 3/4 TEAEs occurring in ⩾ 5% of all patients
Grade 3/4 TEAE, n (%) Escalation (n= 12) MTD with IV bortezomib (n=10) MTD with SC bortezomib (n= 12) Total (N= 34)
Any 11 (92) 9 (90) 9 (75) 29 (85)
Neutropeniaa 4 (33) 8 (80) 3 (25)b 15 (44)
Thrombocytopeniac 3 (25) 4 (40) 2 (17) 9 (26)
Pneumonia 2 (17) 3 (30) 1 (8) 6 (18)
Hypophosphatemia 3 (25) 1 (10) 1 (8) 5 (15)
Blood CPK increase 2 (17) 0 1 (8) 3 (9)
Anemia 1 (8) 0 1 (8) 2 (6)
Fatigue 0 0 2 (17) 2 (6)
Hyperglycemia 1 (8) 1 (10) 0 2 (6)
Hypokalemia 0 2 (20) 0 2 (6)
Dizziness 1 (8) 0 1 (8) 2 (6)
Tremor 1 (8) 1 (10) 0 2 (6)
Abbreviations: CPK, creatinine phosphokinase; IV, intravenous; MTD, maximum tolerated dose; SC, subcutaneous; TEAE, treatment-emergent adverse event.
aNeutropenia includes neutrophil count decreases. bOne patient experienced febrile neutropenia. cThrombocytopenia includes platelet count decreases.
Figure 2. Response outcomes. All treated patients were evaluated
for response (better than or equal to PR). TTR and DOR were
reported for patients who achieved response. BORT, bortezomib; CR,
complete response; sCR, stringent complete response; VGPR, very
good PR.
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we demonstrated that triple therapy with pomalidomide,
bortezomib and LoDEX was highly active, resulting in an ORR
of 65% and disease control in 100%, despite all patients being
refractory to lenalidomide and nearly all having prior exposure to
bortezomib. Responses were durable, lasting a median of
7.4 months. The MTD of the combination regimen was
established at the MPD of pomalidomide 4 mg, IV or SC
bortezomib 1.3 mg/m2 and LoDEX 20 mg (10 mg for patients
aged 475 years). At this therapeutic dose level, 3 patients
achieved sCR/CR.
The regimen of pomalidomide, bortezomib and LoDEX was well
tolerated, and toxicities proved manageable, regardless of mode of
bortezomib administration. Patients were able to receive a median
of 9 cycles of therapy, and no patients discontinued treatment due
to a treatment-related event. The incidences of dose interruptions
and reductions for pomalidomide and bortezomib were consistent
with those of prior studies.13,19 There were also no reports of grade
3/4 peripheral neuropathy, deep vein thrombosis or other toxicities
sometimes associated with immunomodulatory agents and/or
PIs.10,21,23,24 Consistent with the ﬁndings of the SC vs IV bortezomib
phase 3 noninferiority trial, grade 3/4 TEAEs were less frequent with
SC vs IV bortezomib administration.19 However, this ﬁnding may
have been inﬂuenced by fewer patients receiving ⩾ 2 prior lines of
antimyeloma treatment and prior transplant in the SC vs IV
bortezomib cohorts. Patients in the SC cohort also received fewer
cycles of treatment, which may have inﬂuenced the incidence of
TEAEs. The ﬁnding that patients received fewer cycles of SC vs IV
bortezomib may be due to the timing of when patients
discontinued treatment for SCT; 1 patient in the IV group and
2 patients in the SC group went on to receive SCTs.
In studies of pomalidomide plus LoDEX, approximately one-third
of patients with advanced RRMM achieved a tumor response (better
than or equal to PR).25 As demonstrated in this trial and others, the
addition of PIs to IMiD combinations has the potential to lead to
deeper and more durable responses.26–30 Preliminary results of a
phase 1/2 trial of once-weekly bortezomib with pomalidomide and
LoDEX demonstrated a response rate of 85, with 19 and 45% of
patients achieving sCR/CR and at least very good PR, respectively.29
Responses were durable, lasting a median of 13.7 months. This
patient population differed somewhat because o30% of patients
had refractory disease and just over one-half had prior exposure to
bortezomib. In another phase 1 trial with the PI carﬁlzomib, given in
combination with pomalidomide and LoDEX, the ORR was 50%,
with a clinical beneﬁt rate of 66%.28 Similar to data from the phase 1
trial presented here, all patients were refractory to lenalidomide,
although the patients were more heavily pretreated (median 6 prior
regimens (range, 2–12)) and nearly all were refractory to
bortezomib. Results of the phase 1 portion of the Alliance
A061202 study of an oral PI, ixazomib, given in combination with
pomalidomide and LoDEX, demonstrated an ORR of 55% in patients
with RRMM who had received a median of 3 prior lines of therapy
(range, 2–10) and who were refractory to lenalidomide and a PI.26
Pomalidomide-based triple therapy combination regimens with
other drug classes have also demonstrated high antimyeloma
activity in patients with RRMM, including the triple therapy
regimens of pomalidomide plus dexamethasone in combination
with cyclophosphamide (ORR, 65–67%),31,32 the monoclonal
antibodies anti-CD38 (daratumumab; ORR, 71%)33 and anti–
programmed cell death protein 1 (pembrolizumab; ORR, 60%)34
and a histone deacetylase inhibitor (ACY-241; ORR, 46%).35 Taken
together, these studies demonstrate the utility of pomalidomide
and dexamethasone as a platform for combining novel agents.
In conclusion, the MTD of pomalidomide 4 mg, bortezomib
1.3 mg/m2 and LoDEX 20 mg (10 mg for patients aged 475
years) was well tolerated and highly active in patients with
RRMM who were refractory to lenalidomide and had been
previously exposed to bortezomib. These ﬁndings support
further evaluation in clinical trials and suggest that pomalido-
mide, bortezomib and LoDEX may be an important new
treatment option for patients with RRMM. A large randomized,
multicenter, international, phase 3 trial, MM-007 (OPTIMISMM),
to conﬁrm these ﬁndings is currently ongoing and is close to
completing enrollment (ClinicalTrials.gov NCT01734928).
Future directions include the addition of other novel agents to
this platform, such as the monoclonal antibodies discussed
previously, as well as histone deacetylase inhibitors and other
promising next-generation small molecules.36–38
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Table 5. Response outcomes by number of prior lines of therapy
Prior lines of
antimyeloma
therapy
Escalation
(n=12)
MTD with IV
bortezomib
(n=10)
MTD with SC
bortezomib
(n= 12)
1
(n= 4)
⩾ 2
(n= 8)
1
(n=3)
⩾ 2
(n=7)
1
(n= 8)
⩾ 2
(n= 4)
ORR 3 (75.0) 6 (75.0) 2 (66.7) 5 (71.4) 3 (37.5) 3 (75.0)
sCR 0 0 0 1 0 0
CR 0 0 0 0 1 1
VGPR 1 3 1 3 2 1
PR 2 3 1 1 0 1
SD 1 2 1 2 5 1
Progressed/
died after
achieving
response
2 6 2 2 1 1
Abbreviations: CR, complete response; IV, intravenous; MTD, maximum
tolerated dose; ORR, overall response rate; PR, partial response; SC,
subcutaneous; sCR, stringent complete response; SD, stable disease; VGPR,
very good PR.
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